Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.60 |
| ▸ | FNTA | P49354 | 9/20 | 0.40 |
| ▸ | FNTB | P49356 | 7/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455692 | 0.89 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL570052 | 0.89 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| Phosphoric Acid SCHEMBL27686050 | 0.87 | BTN3A1 (0.70) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL30974602 | 0.81 | FNTA (0.39) | BTN3A1FNTAFNTB | |
| SCHEMBL30974607 | 0.81 | BTN3A1 (0.39) | BTN3A1FNTAFNTB | |
| SCHEMBL30974610 | 0.81 | BTN3A1 (0.39) | BTN3A1FNTAFNTB | |
| SCHEMBL30974551 | 0.81 | BTN3A1 (0.39) | BTN3A1FNTAFNTB | |
| SCHEMBL30974545 | 0.81 | BTN3A1 (0.39) | BTN3A1FNTAFNTB | |
| SCHEMBL30974613 | 0.80 | FNTA (0.40) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL30974616 | 0.79 | FNTA (0.42) | BTN3A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2024-08-08 | — | — | US | disclosed |
| EP-4362982-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | Byondis B.V. (NL) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275025-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | CD47, PTMS, PAG1 | BTN3A1 458/4885FNTA 974/4885FNTB 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.